More Antibodies Than Stars: Overhauling Antibody Drug Discovery
Executive Summary
Antiverse co-founder and CEO Murat Tunaboylu, one of In Vivo’s 2022 Rising Leaders, on defining success and why software engineers should consider a career transition to life sciences.
You may also be interested in...
Twist Bioscience: DNA Research Tools Put Fresh Spin On Drug Discovery
Speed and efficiency are fundamental to the success of today’s biopharmaceutical enterprise, but the hunt is still on for transformative technologies to boost pipeline productivity and growth. One answer may lie in the arrival of replicable, synthetic versions of DNA.
California Snaps Up Civica For Biosimilar Insulin Initiative
Civica is set to provide biosimilar insulins to the state of California through its CalRx program, following approval from the US Food and Drug Administration.
Shared Savings Legislation Could Increase Medicare Biosimilar Access
Congressman Richard Hudson has introduced US legislation calling for a three-year ‘demonstration project’ into a shared savings payment scheme for biosimilar medicines provided through Medicare Part B.